The spread of SARS-CoV-2, the virus causing COVID-19, has resulted in a pandemic with heterogeneity in exposure and risk of transmission.1–4 Heterogeneity in social determinants of COVID-19 may exist at the individual and community (e.g., by housing density 5–7) levels. In addition, social determinants of health, including barriers to health care, occupation, structural racism and xenophobia, have been implicated in COVID-19 risk.8,9 Environmental determinants such as ambient air pollution may also play a role, as evidence indicates that higher ambient air pollution increases risk for infection with other respiratory viruses10,11 and the development of severe COVID-19.12,13 Environmental factors are linked with structural racism (e.g., in the context of low-quality housing).12,14 Using observational data to identify risk factors for COVID-19 relies on SARS-CoV-2 testing, a service that is not equally distributed.15 Differential testing introduces the potential for selection biases,16,17 including collider bias.17 Collider bias may be introduced into epidemiologic studies of COVID-19 risk factors if the
factors under investigation are related both to developing an infection and to the likelihood of being tested. For example, data suggest that people with diabetes are more likely to develop severe COVID-19 if infected with SARS-CoV-2. Thus, if infected, people with diabetes may be more likely to be tested, and consequently, diabetes may appear to be associated with a diagnosis of COVID-19 in studies of those tested for SARS-CoV-2, even if diabetes is not a risk factor for infection. The opposite may occur with underlying respiratory diseases (e.g., asthma) that have symptoms similar to those caused by SARS-CoV-2, leading to the appearance of potentially “protective” associations with COVID-19.

Our objectives were to explore the potential for collider bias in a large study of COVID-19 determinants and examine individual, environmental and social determinants associated with testing and diagnosis among 14.7 million people in Ontario, Canada.

Methods

Study population, setting and design

We conducted an observational study using data from population-based laboratory and health administrative databases in Ontario. Ontario’s health system provides universal access to hospital and physician services and laboratory testing. We used data from people who were tested between Mar. 1 and June 20, 2020, to identify determinants associated with testing, and then used 3 analytic designs to identify determinants associated with a positive result for SARS-CoV-2 testing.

Data sources, linkages and inclusion criteria

We identified testing status using data from the Ontario Laboratories Information System (OLIS) and linked this information to relevant health-related data sets containing demographic, health care use and area-level information. These data sets were linked using unique encoded identifiers and analyzed at ICES.

The OLIS captured about 88% of all laboratory-identified SARS-CoV-2 reported by the province during the study period (calculated by cases identified in OLIS divided by the number of cases reported by Ontario’s COVID-19 dashboard in the same time frame). The OLIS records included specimen collection date, results and a text field for symptoms that was completed by health care providers at the time of sampling. We obtained individual- and area-level demographic and environmental information from the Registered Persons Database; the Canadian Institute for Health Information’s Discharge Abstract Database, Same Day Surgery Database and National Ambulatory Care Reporting System; the Ontario Health Insurance Program; the Ontario Mental Health Reporting System; the Ontario Population Health and Environment Cohort; and the 2016 Canada Census (Appendix 1, Supplemental Table 1, available at www.cmaj.ca/lookup/doi/10.1503/cmaj.202608/tab-related-content).

For people with more than 1 test in OLIS, we used the first positive or indeterminate test, or the first negative test if all tests during the study period were negative. We included people who were not tested during the study period if they were not recorded as deceased before or born after Mar. 1, 2020. To assess determinants of testing and diagnosis, we included people who underwent polymerase chain reaction testing for SARS-CoV-2 infection and were not residing in a long-term care facility as of Mar. 1, 2020.

Selection and definition of potential determinants of positive results for SARS-CoV-2 testing

We included sex, age group, underlying health conditions and previous use of health care as individual-level determinants. We selected underlying health conditions as those identified in both the peer- and non-peer-reviewed literature as being associated with COVID-19 severity or with symptoms similar to those of COVID-19, because severity and symptoms may lead to differential testing and thus, collider bias, or conditions that increase the need for personal care support (e.g., dementia), thereby reflecting an intersection with occupational risks among essential care providers.

We hypothesized that health care use would increase access to testing and signal a marker for comorbidities; we measured health care use by the number of hospital admissions in the past 3 years, number of outpatient physician visits in the past year and influenza vaccination in the 2019–2020 season. We also included the Johns Hopkins ACG System Aggregated Diagnostic Groups (ADGs) as a composite measure of comorbidities.

Environmental determinants included fine particulate matter (PM2.5) using satellite-derived estimates and a land-use regression model for NO2 at the postal code level.

We conceptualized social determinants as area-based variables that might signal contact rates in communities (household density; apartment building density; and uncoupled status, e.g., not married); contact rates at work (“essential workers”); socioeconomic barriers to health care access or housing (household income and educational attainment); and factors related to race and ethnicity (visible minority status and recent immigration). We derived these variables from the 2016 Canada Census at the level of dissemination areas (DAs), the smallest geographic unit at which Census data are collected. We ranked dissemination areas at the city level (for median per-person income equivalent) or at the provincial level (for all other social determinants) and then categorized them into quintiles. For apartment building density and recent immigration status, the high frequency of zeros permitted the creation of only 3 categories (i.e., the lower 3 quintiles combined, and the fourth and fifth quintiles).

Statistical analysis

We defined the testing outcome as receipt of at least 1 SARS-CoV-2 test during the study period. The comparator group comprised Ontario residents who had no record of testing during the study period. We evaluated determinants of testing in unadjusted, age- and sex-adjusted, and fully adjusted logistic regression models that included all determinants. The fully adjusted model also included a fixed-effect covariate for public health region. Public health regions are geographic areas in which public health measures were differentially applied, and in which there may be variability in measured and unmeasured social determinants.
To address the potential for collider bias, we compared the odds of a positive test result for SARS-COV-2 derived from unadjusted, age- and sex-adjusted, and fully adjusted logistic regression models (including all determinants and public health regions) using 3 study designs. The “pseudo-test-negative” design compared people who tested positive to people who tested negative; the “true test-negative” design was restricted to tested people who were recorded as having symptomatic illness; and the “case-control” design compared all people with a positive test result with all people without a positive test result (i.e., people with a negative test result or who were not tested).

To identify the determinants of being tested for SARS-CoV-2 and being positive for the virus, we focused on the results from fully adjusted logistic regression models from the pseudo-test-negative and case-control designs; the results using the true test-negative design are provided in Appendix 1. We interpreted each set of determinants as independent analyses based on directed acyclic graphs (Appendix 1, Supplemental Figure 1). We believed that the case-control design had the least potential for collider bias.

We conducted the statistical analysis using SAS version 9.4. To assess for collinearity, we evaluated tolerances and variance inflation factors.

**Ethical approval**
The use of data in this project was authorized under Section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board.

**Results**
Of 758,691 people tested during the study period, 25,030 (3.3%) tested positive for SARS-CoV-2 (Figure 1). Only 11.8% of those tested had a symptom recorded by the provider, 13.6% were considered asymptomatic, and 74.6% were missing symptom information. Descriptive characteristics of our study population are reported in Table 1 and Appendix 1, Supplemental Table 2.

**Determinants of testing for SARS-CoV-2**
In the fully adjusted analysis, we found that the odds of being tested increased with age (Table 2 and Appendix 1, Supplemental Table 3). Males had lower odds of testing than females. We also found that nearly every underlying health condition and most measures of previous use of health care were associated with increased odds of testing. In contrast, higher ambient air pollution was associated with reduced odds of testing. There was little variability in the odds of testing by most area-based social determinants of health. However, areas with higher visible minority populations...
had lower odds of testing, whereas areas with higher household income and greater percentages of uncoupled people had higher odds of testing. The estimates of the odds of being tested for most social determinants of health appeared to be progressively attenuated from unadjusted to age- and sex-adjusted, to fully adjusted regression models. Notably, the direction of the association between testing and income quintile changed direction after adjustment (Figure 2 and Appendix 1, Supplemental Table 3).

Table 1 (part 1 of 2): Characteristics of the study population tested and not tested for SARS-CoV-2 in Ontario (Mar. 1 to June 20, 2020)

| Characteristic | No. (%) of people who were tested* | No. (%) of population of Ontario* |
|---------------|-----------------------------------|----------------------------------|
| Demographic   |                                   |                                  |
| Age, yr; mean ± SD | 49.52 ± 20.99 | 47.45 ± 19.77 |
| Male sex      | 289 769 (39.5) | 11 627 (46.5) |
| Living in rural area or small town† | 82 034 (11.2) | 887 (3.5) |
| Chronic health condition | | |
| Asthma        | 136 556 (18.6) | 3887 (15.5) |
| COPD          | 34 261 (4.7) | 715 (2.9) |
| Hypertension  | 226 111 (30.8) | 7488 (29.9) |
| Diabetes      | 108 758 (14.8) | 4268 (17.1) |
| Congestive heart failure | 35 947 (4.9) | 983 (3.9) |
| Dementia or frailty | 31 804 (4.3) | 1106 (4.4) |
| Cancer†       | 24 333 (3.3) | 484 (1.9) |
| Chronic kidney disease† | 37 630 (5.1) | 1122 (4.5) |
| Immunocompromised§ | 13 325 (1.8) | 319 (1.3) |
| Advanced liver disease | 9020 (1.2) | 212 (0.8) |
| Ischemic heart disease | 33 855 (4.6) | 880 (3.5) |
| Ischemic stroke or TIA¶ | 13 777 (1.9) | 411 (1.6) |
| Schizophrenia** | 7526 (1.0) | 220 (0.9) |
| Substance abuse** | 22 238 (3.0) | 478 (1.9) |
| Health care use | | |
| Adjusted Diagnostic Group (ADG) quintile | | |
| 1 (0 ADGs)   | 31 959 (4.4) | 1571 (6.3) |
| 2 (1–2 ADGs) | 101 895 (13.9) | 3601 (14.4) |
| 3 (3–4 ADGs) | 149 173 (20.3) | 5101 (20.4) |
| 4 (5–6 ADGs) | 150 394 (20.5) | 5115 (20.4) |
| 5 (7–27 ADGs) | 300 240 (40.9) | 9642 (38.5) |
| Hospital admissions in the past 3 yr, mean ± SD | 0.44 ± 1.34 | 0.33 ± 1.21 |
| Outpatient physician visits in the past year, mean ± SD | 7.35 ± 8.68 | 7.06 ± 8.33 |
| Influenza vaccination (2019–2020 season) | 213 722 (29.1) | 5547 (22.2) |
| Environmental determinant†† | | |
| PM<sub>2.5</sub>, (μg/m<sup>3</sup> per yr) | | |
| 2 to < 6   | 161 300 (22.0) | 1831 (7.3) |
| 6 to < 7   | 91 134 (12.4) | 1766 (7.1) |
| 7 to < 8   | 207 966 (28.3) | 8476 (33.9) |
| 8 to < 9   | 211 861 (28.9) | 11 127 (44.5) |
| ≥ 9        | 59 674 (8.1) | 1747 (7.0) |
| NO<sub>x</sub>, (ppb per yr) | | |
| 0 to 6     | 328 613 (44.8) | 5237 (20.9) |
| 6 to 8     | 170 693 (23.3) | 5599 (22.4) |
| ≥ 8        | 232 629 (31.7) | 14 111 (56.4) |
| Social determinant of health‡‡ (area level) | | |
| Household density quintile§§ | | |
| 1 (0–2.1) | 162 623 (22.2) | 3639 (14.5) |
| 2 (2.2–2.4) | 140 653 (19.2) | 3104 (12.4) |
| 3 (2.5–2.6) | 104 896 (14.3) | 2721 (10.9) |
| 4 (2.7–3.0) | 166 089 (22.6) | 6321 (25.3) |
| 5 (3.1–5.7) | 152 578 (20.8) | 8929 (35.7) |
Table 1 (part 2 of 2): Characteristics of the study population tested and not tested for SARS-CoV-2 in Ontario (Mar. 1 to June 20, 2020)

| Characteristic | No. (%) of people who were tested* | No. (%) of population of Ontario* |
|----------------|-----------------------------------|-----------------------------------|
|                | Negative test result n = 733 661 | Positive test result n = 25 030 |
| Apartment building density category¶¶¶ | 1 (0%–7.3%) | 391 477 (53.4) |
|                | 2 (7.4%–37.7%) | 145 108 (19.8) |
|                | 3 (37.7%–104%) | 190 244 (25.9) |
| Uncoupled quintile*** | 1 (11.2%–33.7%) | 150 044 (20.5) |
|                | 2 (33.7%–38.4%) | 128 561 (17.5) |
|                | 3 (38.5%–43.6%) | 127 689 (17.4) |
|                | 4 (43.6%–51.0%) | 145 560 (19.8) |
|                | 5 (51.0%–94.6%) | 174 985 (23.9) |
| Essential worker status††† | 1 (0%–2.2%) | 150 517 (19.8) |
|                | 2 (2.2%–7.5%) | 145 189 (21.2) |
|                | 3 (7.5%–11.4%) | 149 589 (20.4) |
|                | 4 (11.4%–17.1%) | 143 965 (19.6) |
|                | 5 (17.1%–94.6%) | 133 601 (18.2) |
| Household income quintile†‡‡ | 1 (lowest income) | 156 320 (21.3) |
|                | 2 | 148 687 (20.3) |
|                | 3 | 145 317 (19.8) |
|                | 4 | 140 352 (19.1) |
|                | 5 (highest income) | 138 103 (18.8) |
| Limited educational attainment quintile§§§ | 1 (0.0%–4.1%) | 144 457 (19.7) |
|                | 2 (4.1%–7.5%) | 154 215 (21.0) |
|                | 3 (7.5%–11.4%) | 151 457 (20.6) |
|                | 4 (11.4%–17.1%) | 148 159 (20.2) |
|                | 5 (17.1%–94.6%) | 129 580 (17.7) |
| Visible minority quintile¶¶¶ | 1 (0.0%–2.1%) | 130 912 (17.8) |
|                | 2 (2.2%–7.5%) | 137 826 (18.8) |
|                | 3 (7.5%–18.7%) | 137 744 (18.8) |
|                | 4 (18.7%–43.5%) | 153 503 (20.9) |
|                | 5 (43.5%–102%) | 167 893 (22.9) |
| Recent immigration category**** | 1 (0.0%–2.1%) | 401 300 (54.7) |
|                | 2 (2.1%–4.7%) | 146 772 (20.0) |
|                | 3 (4.7%–14.2%) | 174 829 (23.8) |

Note: ADG = Aggregated Diagnostic Group, COPD = chronic obstructive pulmonary disease, DA = dissemination area, PM2.5 = fine particulate matter, SD = standard deviation, TIA = transient ischemic attack.

*Unless stated otherwise.
†We defined rural as being located outside the commuting zone of a city with a population greater than 10 000.
‡We considered people to be unimmunocompromised if they were HIV positive, had an organ or bone marrow transplant, or had another immunodeficient condition.
§We considered people to be immunocompromised if they were HIV positive, had an organ or bone marrow transplant, or had another immunodeficient condition.
¶¶The Census counts are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision: 7.3% represents the 60th percentile.
‡‡All variables in this category are area-level variables at the level of the 2016 Canada Census DA.
***Uncoupled people are those never married (people who have never legally married and are not living with a person as a couple); separated people who are married but who are no longer living with their spouse (for reasons other than, e.g., illness, work or school), have not obtained a divorce and are not living with a person as a couple; divorced (people who have obtained a legal divorce, have not remarried and are not living with a person as a couple); and widowed (people who have lost their married spouse through death, have not remarried and are not living with a person as a couple).
****Uncoupled people are those never married (people who have never legally married and are not living with a person as a couple); separated people who are married but who are no longer living with their spouse (for reasons other than, e.g., illness, work or school), have not obtained a divorce and are not living with a person as a couple; divorced (people who have obtained a legal divorce, have not remarried and are not living with a person as a couple); and widowed (people who have lost their married spouse through death, have not remarried and are not living with a person as a couple).
†††Percentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.
‡‡‡Income quintile has variable cut-off values in each city or Census area, to take cost of living into account. A DA being in quintile 1 means it is among the lowest 20% of DAs in its city by income.
§§§Percentage of adults aged 25–64 yr in the area who have not received any type of diploma.
¶¶¶Percentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.
*Unless stated otherwise.
Table 2 (part 1 of 2): Odds of ever being tested for SARS-CoV-2 and of COVID-19 diagnosis in Ontario between Mar. 1 and June 20, 2020, in fully adjusted analyses using 2 analytic designs

| Determinant | Tested v. not tested | Test-positive v. test-negative among all people tested† | Test-positive v. not test-positive‡§ |
|-------------|----------------------|-------------------------------------------------------|-----------------------------------|
|             | adjusted OR (95% CI) | adjusted OR (95% CI)                                  | adjusted OR (95% CI)              |
| Sample size | 14 695 579           | 758 691                                               | 14 695 579                        |
| Individual determinant |     |                                                     |                                   |
| Age group, yr (Ref. 0–4) |     |                                                     |                                   |
| 5–19        | 1.15 (1.13–1.18)     | 1.93 (1.66–2.24)                                      | 1.72 (1.49–1.99)                 |
| 20–34       | 4.13 (4.05–4.22)     | 2.00 (1.75–2.30)                                      | 7.03 (6.13–8.05)                 |
| 35–49       | 4.13 (4.05–4.21)     | 1.98 (1.73–2.27)                                      | 6.74 (5.88–7.73)                 |
| 50–64       | 4.21 (4.12–4.29)     | 2.02 (1.76–2.32)                                      | 7.01 (6.11–8.03)                 |
| 65–74       | 3.04 (2.98–3.11)     | 1.62 (1.40–1.87)                                      | 3.99 (3.46–4.60)                 |
| 75–84       | 3.01 (2.95–3.08)     | 1.64 (1.41–1.90)                                      | 3.94 (3.39–4.57)                 |
| ≥ 85        | 5.60 (5.47–5.73)     | 1.76 (1.51–2.06)                                      | 7.26 (6.23–8.46)                 |
| Male sex    | 0.76 (0.76–0.76)     | 1.26 (1.23–1.30)                                      | 1.00 (0.98–1.03)                 |
| Living in rural area or small town¶ | 0.97 (0.96–0.98)   | 0.81 (0.74–0.88)                                      | 0.76 (0.70–0.82)                 |
| Underlying chronic health condition |     |                                                     |                                   |
| Asthma      | 1.09 (1.09–1.10)     | 0.86 (0.83–0.89)                                      | 0.92 (0.89–0.96)                 |
| COPD        | 1.23 (1.21–1.24)     | 0.89 (0.82–0.96)                                      | 1.04 (0.96–1.13)                 |
| Hypertension| 0.98 (0.98–0.99)     | 1.12 (1.08–1.16)                                      | 1.13 (1.09–1.17)                 |
| Diabetes    | 0.98 (0.97–0.99)     | 1.26 (1.21–1.31)                                      | 1.19 (1.14–1.23)                 |
| Congestive heart failure | 1.26 (1.24–1.28) | 0.99 (0.92–1.07)                                      | 1.25 (1.16–1.35)                 |
| Dementia or frailty score > 15 | 2.12 (2.09–2.15) | 1.39 (1.29–1.49)                                      | 2.60 (2.42–2.80)                 |
| Cancer†     | 1.13 (1.12–1.15)     | 0.72 (0.66–0.80)                                      | 0.86 (0.78–0.94)                 |
| Chronic kidney disease** | 1.31 (1.29–1.32) | 0.86 (0.80–0.93)                                      | 1.16 (1.08–1.24)                 |
| Immunocompromised†† | 1.30 (1.28–1.33) | 0.79 (0.70–0.89)                                      | 1.02 (0.91–1.14)                 |
| Advanced liver disease | 1.14 (1.11–1.16) | 0.79 (0.68–0.90)                                      | 0.87 (0.76–1.00)                 |
| Ischemic heart disease | 1.02 (1.01–1.03) | 0.88 (0.82–0.95)                                      | 0.90 (0.84–0.97)                 |
| Ischemic stroke or TIA‡‡ | 1.15 (1.13–1.17) | 1.05 (0.95–1.17)                                      | 1.18 (1.06–1.31)                 |
| Schizophrenia§§ | 1.24 (1.21–1.27) | 0.84 (0.73–0.97)                                      | 0.99 (0.87–1.13)                 |
| Substance abuse§§ | 1.17 (1.16–1.19) | 0.72 (0.66–0.79)                                      | 0.86 (0.79–0.95)                 |
| Health care use |     |                                                     |                                   |
| Aggregated Diagnostic Group (ADG) quintile (Ref. = 0 ADGs) |     |                                                     |                                   |
| 2 (1–2 ADGs) | 1.64 (1.62–1.66) | 0.78 (0.73–0.84)                                      | 1.24 (1.17–1.32)                 |
| 3 (3–4 ADGs) | 2.07 (2.04–2.10) | 0.75 (0.70–0.80)                                      | 1.46 (1.37–1.56)                 |
| 4 (5–6 ADGs) | 2.44 (2.41–2.48) | 0.74 (0.69–0.79)                                      | 1.69 (1.57–1.81)                 |
| 5 (7–27 ADGs) | 3.11 (3.06–3.15) | 0.75 (0.69–0.80)                                      | 2.12 (1.97–2.28)                 |
| Hospital admissions in the past 3 yr (Ref. = 0 admissions) |     |                                                     |                                   |
| 1           | 0.99 (0.98–1.00)     | 0.93 (0.89–0.97)                                      | 0.92 (0.88–0.96)                 |
| 2           | 1.16 (1.14–1.17)     | 0.86 (0.79–0.93)                                      | 1.01 (0.94–1.09)                 |
| ≥ 3         | 1.75 (1.73–1.78)     | 0.82 (0.76–0.90)                                      | 1.38 (1.27–1.50)                 |
| Outpatient physician visits in the past yr (Ref. = 0–1 visits) |     |                                                     |                                   |
| 2–4         | 1.08 (1.07–1.09)     | 1.02 (0.98–1.07)                                      | 1.12 (1.08–1.18)                 |
| 5–8         | 1.11 (1.10–1.12)     | 1.01 (0.98–1.08)                                      | 1.17 (1.11–1.23)                 |
| 9–14        | 1.17 (1.16–1.18)     | 0.98 (0.93–1.04)                                      | 1.17 (1.10–1.24)                 |
| ≥ 15        | 1.36 (1.34–1.37)     | 0.91 (0.85–0.97)                                      | 1.22 (1.14–1.30)                 |
| Influenza vaccination (2019–2020 season) | 1.08 (1.08–1.09) | 0.81 (0.78–0.83)                                      | 0.87 (0.85–0.90)                 |
| Environmental determinants¶¶ |     |                                                     |                                   |
| PM2.5 category (μg/m³) (Ref. = 2–6) |     |                                                     |                                   |
| 6–7         | 0.97 (0.97–0.98)     | 0.91 (0.85–0.99)                                      | 0.92 (0.85–0.99)                 |
| 7–8         | 0.92 (0.90–0.93)     | 1.10 (0.99–1.21)                                      | 1.00 (0.91–1.10)                 |
| 8–9         | 0.91 (0.90–0.93)     | 1.29 (1.16–1.43)                                      | 1.19 (1.08–1.32)                 |
| ≥ 10        | 0.90 (0.89–0.92)     | 1.45 (1.29–1.63)                                      | 1.31 (1.16–1.47)                 |
| NO2 category (ppb) (Ref. = 0–6) |     |                                                     |                                   |
| 6–8         | 0.95 (0.95–0.96)     | 1.05 (1.00–1.11)                                      | 1.00 (0.96–1.06)                 |
| ≥ 8         | 0.94 (0.93–0.95)     | 1.13 (1.06–1.21)                                      | 1.05 (0.98–1.12)                 |
Table 2 (part 2 of 2): Odds of ever being tested for SARS-CoV-2 and of COVID-19 diagnosis in Ontario between Mar. 1 and June 20, 2020, in fully adjusted analyses using 2 analytic designs

| Determinant | People tested for SARS-CoV-2 | People with a diagnosis of COVID-19* |
|-------------|-----------------------------|-------------------------------------|
|             | Tested v. not tested         | Test-positive v. test-negative among | Test-positive v. not test-positive§§ |
|             | adjusted OR (95% CI)         | all people tested†                 | adjusted OR (95% CI)                |
| Household density quintile†† (Ref. = first quintile) | | | |
| 2 | 1.01 (1.00–1.02) | 1.21 (1.14–1.27) | 1.19 (1.13–1.26) |
| 3 | 1.03 (1.02–1.04) | 1.39 (1.31–1.48) | 1.42 (1.34–1.50) |
| 4 | 1.01 (1.00–1.02) | 1.70 (1.61–1.79) | 1.70 (1.61–1.80) |
| 5 | 0.97 (0.95–0.98) | 1.94 (1.82–2.07) | 1.86 (1.75–1.98) |
| Apartment building density category††† (Ref. = first category) | | | |
| 2 | 1.04 (1.03–1.04) | 1.00 (0.95–1.04) | 1.02 (0.98–1.06) |
| 3 | 1.01 (1.00–1.02) | 1.15 (1.09–1.21) | 1.18 (1.12–1.24) |
| Uncoupled quintile§§§ (Ref. = first quintile) | | | |
| 2 | 1.02 (1.01–1.03) | 0.96 (0.91–1.01) | 0.97 (0.92–1.02) |
| 3 | 1.07 (1.06–1.08) | 0.95 (0.90–1.00) | 0.99 (0.94–1.04) |
| 4 | 1.19 (1.18–1.21) | 0.96 (0.91–1.02) | 1.11 (1.05–1.17) |
| 5 | 1.39 (1.38–1.41) | 1.07 (1.01–1.15) | 1.41 (1.32–1.51) |
| Essential work quintile¶¶¶ (Ref. = first category) | | | |
| 2 | 1.04 (1.03–1.04) | 1.25 (1.19–1.32) | 1.30 (1.24–1.37) |
| 3 | 1.06 (1.05–1.07) | 1.28 (1.21–1.35) | 1.37 (1.30–1.45) |
| 4 | 1.05 (1.04–1.06) | 1.37 (1.29–1.45) | 1.51 (1.42–1.60) |
| 5 | 1.04 (1.03–1.06) | 1.42 (1.32–1.51) | 1.58 (1.48–1.69) |
| Household income quintile (Ref. = first quintile, lowest income)**** | | | |
| 2 | 1.03 (1.02–1.04) | 0.96 (0.91–1.00) | 1.00 (0.96–1.05) |
| 3 | 1.08 (1.07–1.09) | 1.02 (0.97–1.08) | 1.12 (1.06–1.18) |
| 4 | 1.10 (1.09–1.11) | 0.97 (0.90–1.03) | 1.06 (1.00–1.13) |
| 5 | 1.11 (1.09–1.12) | 0.97 (0.90–1.04) | 1.07 (0.99–1.15) |
| Limited educational attainment quintile†††† (Ref. = first quintile) | | | |
| 2 | 1.03 (1.02–1.04) | 1.07 (1.02–1.12) | 1.09 (1.04–1.15) |
| 3 | 1.01 (1.00–1.02) | 1.15 (1.09–1.21) | 1.15 (1.09–1.21) |
| 4 | 1.02 (1.01–1.03) | 1.23 (1.17–1.30) | 1.21 (1.15–1.28) |
| 5 | 1.01 (1.00–1.02) | 1.37 (1.29–1.46) | 1.33 (1.26–1.41) |
| Visible minority quintile††††† (Ref. = first category) | | | |
| 2 | 0.99 (0.98–1.00) | 0.96 (0.91–1.02) | 0.95 (0.89–1.02) |
| 3 | 0.95 (0.94–0.96) | 0.97 (0.91–1.01) | 0.93 (0.87–1.00) |
| 4 | 0.91 (0.90–0.92) | 1.07 (0.99–1.15) | 0.98 (0.91–1.06) |
| 5 | 0.86 (0.85–0.87) | 1.27 (1.17–1.38) | 1.09 (1.00–1.19) |
| Recent immigration category§§§§ (Ref. = first category) | | | |
| 2 | 0.99 (0.99–1.00) | 1.04 (1.00–1.09) | 1.04 (1.00–1.08) |
| 3 | 0.94 (0.93–0.95) | 1.16 (1.11–1.22) | 1.10 (1.05–1.15) |

Note: ADG = Aggregated Diagnostic Group, COPD = chronic obstructive pulmonary disease, OR = odds ratio, PM_{2.5} = fine particulate matter, Ref. = reference category, TIA = transient ischemic attack.
*All presented models are fully adjusted and contain all variables listed in this table as covariates.
†Pseudo-test-negative design.
‡That is, all negative tests and all untested people.
§Case-control design.
¶Values of PM_{2.5} > 12 μg/m^3 or NO_{2} > 53 ppb per year have been found to be associated with increased risk of other respiratory illnesses.52
§§All variables in this category are area-level variables at the level of the 2016 Canada Census dissemination area (DA).
||First quintile represents 0–2.1 people/dwelling; second quintile, 2.2–2.4 people/dwelling; third quintile, 2.5–2.6 people/dwelling; fourth quintile, 2.7–3 people/dwelling; and fifth quintile, 3.1–5.7 people/dwelling.
||First category, 0%–7.3% of buildings in the area are apartment buildings; second category, 7.4%–37.7% are apartment buildings; and third category, 37.7%–100% are apartment buildings.
§§§§First quintile, 0%–2.1% of people in a DA being recent immigrants; second category, 2.1%–4.7% of people; and third category, 4.7%–41.2% of people.
---

People tested for SARS-CoV-2

- Tested v. not tested adjusted OR (95% CI)
- Test-positive v. test-negative among all people tested† adjusted OR (95% CI)
- Test-positive v. not test-positive§§ adjusted OR (95% CI)
Variability in determinants of a positive result for SARS-CoV-2 testing across analytic designs

Our comparison of results using the different analytic designs showed important differences in individual-level determinants and fewer differences in social determinants (Table 2 and Appendix 1, Supplemental Tables 4–6). Variables that were associated with testing tended to show different relations with SARS-CoV-2 positivity across study designs. For example, the adjusted odds of being tested for adults aged 85 years or older compared with those younger than 5 years was 5.60 (95% confidence interval [CI] 5.47–5.73), and the adjusted odds of being positive for SARS-CoV-2 infection was 1.76 (95% CI, 1.51–2.06) with the pseudo-test-negative design and 7.26 (95% CI, 6.23–8.46) for the case–control design (Table 2).

Determinants of a positive test result for SARS-CoV-2 using the case–control design

Using the case–control design, we found that older age, certain comorbidities (i.e., hypertension, diabetes, congestive heart failure, dementia, chronic kidney disease and ischemic stroke/transient ischemic attack) and increased previous use of health care were associated with increased odds of a positive SARS-CoV-2 test result. Other comorbidities (i.e., asthma, cancer, ischemic heart disease and substance abuse) and receipt of influenza vaccine in the 2019–2020 season were associated with reduced odds of a positive test result (Table 2 and Appendix 1, Supplemental Table 6). The 2 highest categories of PM$_{2.5}$ exposure were associated with increased odds of being positive, whereas no categories of exposure to NO$_{2}$ were associated with increased odds of positivity.
We also found that higher household density, increased apartment building density, greater percentages of uncoupled people and greater percentages of essential workers were associated with greater odds of a positive SARS-CoV-2 test. Lower educational attainment was related to increased odds, but there was no statistically consistent relation with household income. We also determined that being in the highest quintile of neighbourhoods with visible minorities and greater percentages of recent immigrants were associated with greater odds of a positive SARS-CoV-2 test result. Associations were attenuated after adjustment for all social determinants except for household density and essential work (Figure 3 and Appendix 1, Supplemental Table 6).

Our evaluation of collinearity diagnostics found that all tolerances were below 1 and all variance inflation factors were below 5 (Appendix 1, Supplemental Table 7).

**Interpretation**

We found that our 3 analytic designs identified different individual determinants of positive test results for SARS-CoV-2, likely because of collider bias. Using the case–control analysis, which we considered the least biased, we identified particular individual, environmental, and social determinants of health as key determinants for testing positive for SARS-CoV-2.

Using the true test-negative and pseudo-test-negative designs we found a high potential for erroneously identifying some individual determinants, such as underlying health conditions as protective against testing positive for SARS-CoV-2, although they were associated with higher rates of being tested. These health conditions are associated with COVID-19 severity² and may have been prone to collider bias, where the direction of effect measures changes based on model choice. Similar results were found with health care use variables. Thus, assessment of determinants for SARS-CoV-2 positive test results require careful interpretation by evaluation of the reasons for testing.¹⁷ In the context of low overall levels of testing, the case–control design appears to have mitigated some potential sources of collider bias, with the assumption that those not tested are similar to those who tested negative.¹⁶,¹⁷

We found that some underlying health conditions remained associated with diagnoses using the case–control design, reflecting either unmeasured confounding or possible biological susceptibility...
to infection if exposed. For example, dementia and frailty remained independently associated with diagnosis, which may have been due to unmeasured confounding such as higher rates of contacts with caregivers or residence in other types of congregate settings such as retirement homes. Thus, underlying health conditions like dementia and frailty represent targets for prevention with strategies tailored to reduce exposures among people characterized by these individual determinants.

During the study period, the testing criteria for SARS-CoV-2 in Ontario shifted from a focus on returning symptomatic travellers to people who were severely symptomatic and those with occupational exposure to additional testing of people who were asymptomatic. These changes may have created differences among people who were tested and had symptoms compared with all people who were tested. In our study, the restriction of the test-negative design to people with symptoms did not yield substantially different results than the test-negative design that included symptomatic and asymptomatic people for most determinants, but this may have been due, in part, to the high proportion of people who were missing symptom information (74.6%).

The independent association between high PM$_{2.5}$ and diagnosis may reflect unmeasured social determinants of health. However, studies have also implicated environmental pollution as having a biological relation to the risk and severity of COVID-19. We identified increased odds of a positive test result for SARS-CoV-2 associated with household density, apartment building percentage, uncoupled status, essential work, educational attainment and recent immigration, consistent with findings from other settings. Households with high density have been shown to be a consistent risk factor across a broad range of settings. These higher infection rates are likely due to prolonged and physically closer in-person contacts occurring more frequently within the household. Essential services and occupations have also been associated with higher exposure risk, either because such jobs cannot be done feasibly with proper protections or because protective policies and materials are not issued, leaving workers at high risk.

We found that higher percentages of recent immigrants in an area were associated with a positive test result for SARS-CoV-2, even after adjustment, although the percentage of visible minorities was not. Both variables might represent residual measures of structural racism, potentiating increased risk of SARS-CoV-2 exposure and COVID-19 severity, including hospital admission and death related to COVID-19. We found the association between visible minority status and diagnosis was attenuated after adjustment for individual, environmental and other social determinants of health. Finally, because there was little association between most social determinants and the odds of testing suggests that testing resources may not be adequately prioritized to people at greatest risk.

Our findings suggest a need to increase and redirect resources that specifically address social determinants such as household density, occupational risk, workplace testing and improved ventilation and other mediators of structural racism and, community-led outreach testing. Our findings also suggest prioritizing COVID-19 vaccination strategies that reach communities and workplaces having the highest rates of cases. Although the Chief Public Health Officer of Canada has suggested an equity lens to the public health response to COVID-19, much of the response on COVID-19 equity and outreach to marginalized communities to date has been accomplished through smaller independent groups, including volunteer organizations.

**Limitations**

Our determination of positive test results for SARS-CoV-2 was restricted to laboratory-confirmed cases and to the 88% of total provincial diagnoses that were available via OLIS. We assumed that determinants remained constant across the study period, whereas surveillance data suggest shifts in how infections propagate between social networks. Future analysis should evaluate changes in the direction and size of determinants over the course of the outbreak. Our models also adjusted for public health region, within which many social determinants cluster, and we cannot infer from our results how social determinants of diagnosis may vary among and within these geographic regions. We measured social determinants at the area level and these determinants were not available at the individual level; however, by describing individuals’ neighbourhoods, our analysis reflected the role of structural and environmental determinants for people living in them. We may have over-adjusted in the fully adjusted models in our analysis because of the large number of covariates. However, the directions of effect estimates generally remained the same after full adjustment, and the sample size of our analyses provided adequate statistical power. Finally, some relevant determinants, such as obesity, were not available for our study.

**Conclusion**

We found that demographic and health-related risks for positive test results for SARS-CoV-2, which generally have been the targets of response strategies against COVID-19 to date, appeared subject to collider bias. However, we observed consistent relations between testing positive for SARS-CoV-2 and key social determinants of health, including essential worker status, number of people living in a household and educational attainment. Effective responses to COVID-19 require that the social determinants associated with access to testing and SARS-CoV-2 transmission risks be characterized and addressed using risk-tailored, community-based interventions.

**References**

1. Mishra S, Kwong JC, Chan AK, et al. Understanding heterogeneity to inform public health response to COVID-19 in Canada. CMAJ 2020;192:E684-5.
2. Report of the WHO–China joint mission on coronavirus disease 2019 (COVID-19). Geneva: World Health Organization; 2020.
3. Rosenberg ES, Dufort EM, Blog DS, et al.; New York State Coronavirus 2019 Response Team. COVID-19 testing, epidemic features, hospital outcomes, and associated determinants [preprint]. MedRxiv 2020 Apr. 15. doi: 10.1101/2020.04.11.20056010.
4. Jing Q-L, Liu M-J, Yuan J, et al. Household secondary attack rate of COVID-19 and associated determinants [preprint]. MedRxiv 2020 Apr. 15. doi: 10.1101/2020.04.11.20056010.
5. Bhatia N, Curry G, Martineau AR, et al. Sharpening the global focus on ethnicity and race in the time of COVID-19. Lancet 2020;395:1673-6.
6. Chung H, Fung K, Ferreira-Legere LE, et al. COVID-19 Laboratory testing in Ontario: patterns of testing and characteristics of individuals tested, as of April 30, 2020. Toronto: ICES; 2020.
7. Wang L, Ma H, Yi KCY, et al. Heterogeneity in risk, testing and outcome of COVID-19 across outbreak settings in the Greater Toronto Area, Canada: an observational study. CJAM Open 2020;6:E627-36.
8. Price-Haywood EG, Burszcyk J, Fort D, et al. Hospitalization and mortality among black patients and white patients with COVID-19. N Engl J Med 2020;392:2534-43.
9. Yehia BR, Vinegar A, Fogel R, et al. Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals. JAMA Netw Open 2020;3:e2018039.
10. Feng C, Li J, Sun W, et al. Impact of ambient fine particulate matter (PM) exposure on the risk of influenza-like illness: a time-series analysis in Beijing, China. Environ Health 2016;15:17.
11. Zoran MA, Savastru RS, Savastru DM, et al. Assessing the relationship between surface levels of PM2.5 and PM10, particulate matter impact on COVID-19 in Milan, Italy. Sci Total Environ 2020;738:119821.
12. Wu X, Nethery RC, Sabath BM, et al. Exposure to air pollution and COVID-19 mortality in the United States: a nationwide cross-sectional study. Sci Adv 2020;6:eabd4049.
13. Liang D, Shi L, Zhao J, et al. Urban air pollution may enhance COVID-19 case-fatality and mortality rates in the United States. Innovation (NY) 2020;1:100047.
14. The Lancet Planetary Health. Environmental racism: time to tackle social injustices. Lancet Planet Health 2018;2:e462.
15. Stall NM, Wu W, Lapointe-Shaw L, et al. Sex- and age-specific differences in COVID-19 testing and outcomes: a population-wide study in Ontario, Canada. J Am Geriatr Soc 2020;68:2188-91.
16. Niedzwiedz CL, O’Donnell CA, Jani BD, et al. Ethnic and socioeconomic differences in COVID-19 versus patients with influenza [preprint]. Lancet Respir Med 2020;8:e21.
17. Griffith GJ, Morris TT, Tuibball MJ, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun 2020;11:5749.
18. Hernán MA, Robins JM. Causal inference: what if. Boca Raton (FL): Chapman & Hall/CRC; 2020.
19. Elwert F, Winship C. Endogenous selection bias: the problem of conditioning on a collider variable. Anna Rev Sociol 2014;40:31-53.
20. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: knowledge in progress. Diabetes Res Clin Pract 2020;162:108142.
21. Kumar A, Aora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr 2020;14:535-45.
22. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020;108:154262.
23. Health care in Ontario: OHIP. Toronto: Government of Ontario. Available: www.ontario.ca/page/health-care-ontario (accessed 2020 Oct. 29).
24. Schedule of benefits for laboratory services. Toronto: Ministry of Health and Long-Term Care; 2020.
25. ICES. Data, Discovery, Better Health. Toronto: ICES; 2020. Available: www.ices.on.ca/Data-and-Privacy/ICES-data/Types-of-ICES-Data (accessed 2020 Oct. 29).
26. Data products, 2016 Census. Ottawa: Statistics Canada; modified 2021 Feb. 8. Available: www12.statcan.gc.ca/census-recensement/2016/dp-pd/index-eng.cfm (accessed 2020 Oct. 29).
27. Pennington E. Asthma increases risk of severity of COVID-19. Cleve Clin J Med 2020 May 5 [Epub ahead of print]. doi: 10.3949/ccjm.87a.ccc002.
28. Williamson EJ, Walker AJ, Bhaskaran K, et al. OPENSAFE: factors associated with COVID-19 death in 17 million patients. Nature 2020;584:430-6.
29. Fang L, Karakulias G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8.e21.
30. Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with COVID-19 versus patients with influenza [preprint]. medRxiv 2020 May 21 doi: 10.1101/2020.05.18.20105494.
31. COVID-19 provincial testing guidance update. V. 4.0, May 4, 2020. Toronto: Ministries of Health and Long-Term Care.
32. COVID-19 provincial testing guidance update: May 2, 2020. Toronto: Ministries of Health and Long-Term Care.
33. COVID-19 provincial testing guidance update: April 30, 2020. Toronto: Ministries of Health and Long-Term Care.
34. COVID-19 provincial testing guidance update: May 28, 2020. Toronto: Ministries of Health and Long-Term Care.
35. COVID-19 quick reference public health guidance on testing and clearance. Toronto: Ministries of Health and Long-Term Care; 2020.
36. COVID-19 provincial testing guidance update: April 8, 2020. Toronto: Ministries of Health and Long-Term Care.
66. Liem A, Wang C, Wariyanti Y, et al. The neglected health of international migrant workers in the COVID-19 epidemic. Lancet Psychiatry 2020;7:e20.

67. Ordóñez CE. Not race, racism: concerns of COVID-19 affecting African Americans. Anthropological Responses to Health Emergencies; 2020.

68. Vazquez J, Islam T, Beller J, et al. Expanding paid sick leave as a public health adaptation are made. See: https://creativecommons.org/licenses/ provided that the original publication is properly cited, the use is non- commercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/ by-nc-nd/4.0/

69. Brandén M, Aradhya S, Kolk M, et al. Residential context and COVID-19 mortality among adults aged 70 years and older in Stockholm: a population-based, observational study using individual-level data. Lancet Healthy Longev 2020;1:e80-8.

70. Jordan-Martin NC, Madad S, Alves L, et al. Isolation hotels: a community-based intervention to mitigate the spread of the COVID-19 pandemic. Health Secur 2020 Sept 25. [Epub ahead of print]. doi: 10.1089/hs.2020.0123.

71. Madad S, Nuzzo JB, Bordeaux M. The missing piece in America’s COVID-19 isolation and quarantine strategy: wraparound services [blog]. Health Affairs 2020 Dec 10. Available: www.healthaffairs.org/do/10.1377/hblog20201207.458415/full/ (accessed 2021 Mar 9).

72. Vazquez J, Islam T, Beller J, et al. Expanding paid sick leave as a public health tool in the COVID-19 pandemic. J Occup Environ Med 2020;62:e598-9.

73. Rapid COVID-19 testing a potential game-changer in worker protection. Toronto: Institute for Work and Health; 2020. Available: www.iwh.on.ca/newsletters/at-work/102/rapid-covid-19-testing-potential-game-changer-in-worker-protection (accessed 2021 Mar 9).

74. Webb Hooper M, Naples AM, Perez-Stable EJ. COVID-19 and racial/ethnic disparities. JAMA 2020;323:2466-7.

75. Yang T-C, Choi S-WE, Sun F. COVID-19 cases in US counties: roles of racial/ethnic density and residential segregation. Elfin Health 2021;26:11-21.

76. Wallis G, Siracusci F, Blank M, et al. Experience of a novel community testing programme for COVID-19 in London: lessons learnt. Clin Med (Lond) 2020;20:e165-9.

77. Good Neighbour Project [home page]. Available: www.goodneighbourproject. com (accessed 2021 Feb 22).

78. Marwaha S, Vohra-Miller S, Grewal R. We started the South Asian COVID Task Force because Ontario failed to address inequities. In a short time, we’ve seen more people get tested. Toronto Star 2020 Dec 17. Available: www.thestar.com/opinion/ contributors/2020/12/15/we-started-the-south-asian-covid-task-force-because -ontario-failed-to-address-inequities-in-a-short-time-weve-been-able-to-make -great-strides.html (accessed 2021 Feb 22).

79. Jabakhanji S. Meet the Toronto Indigenous organizations bringing COVID-19 testing, food directly to people’s doorsteps. CBC News Toronto 2020 Dec 19. Available: www.cbc.ca/news/canada/toronto/anishnawbe-health-toronto -mobile-unit-covid-19-1.5841393 (accessed 2021 Feb 22).

80. Kwock S, Adam S, Ho JH, et al. Obesity: a critical risk factor in the COVID-19 pandemic. Clin Obes 2020;10:e12403.

81. ICES Data Dictionary. Toronto: ICES. Available: www.ices.on.ca/Data-and-Privacy/ ICES-data/Data-dictionary (accessed 2020 Nov. 1).

Competing interests: Adrienne Chan is a member of the board of Partners in Health Canada. Mackenzie Hamilton is currently serving an internship at AstraZeneca Canada in support of health research initiatives in lupus and severe asthma. No other competing interests were declared.

This article has been peer reviewed.

Affiliations: ICES Central (Sundaram, Calzavara, Hamilton, Djebli, Rosella, Watson, H. Chen, B. Chen, Kwong); Department of Medicine (Mishra, Chan); Institute of Health Policy, Management and Evaluation (Mishra; Chan); Institute of Medical Science (Mishra); Dalla Lana School of Public Health (Kustra, Chan, Hamilton, Djebli, Rosella, Watson, H. Chen, Kwong); Department of Statistical Sciences (Kustra); and Department of Family and Community Medicine (Kwong), University of Toronto; MAP Centre for Urban Health Solutions (Mishra), Li Ka Shing Knowledge Institute, St. Michael’s Hospital, Unity Health Toronto; Sunnybrook Health Sciences Centre (Chan); Public Health Ontario (Kwong, H. Chen); University Health Network (Kwong), Toronto, Ont.; Department of Epidemiology (Baral), Johns Hopkins Bloomberg School of Public Health, Baltimore, Md.

Contributors: Jeffrey Kwong, Sharmistha Mishra and Stefan Baral designed the study. Andrew Calzavara conducted all data analyses (data set and variable creation and statistical modelling). Jeffrey Kwong, Sharmistha Mishra, Stefan Baral, Rafal Kustra and Andrew Calzavara designed the analysis plans and conducted variable selection, with input from Hong Chen and Adrienne Chan on variable selection and definitions. Mackenzie Hamilton, Mohamed Djebli, Laura Rosella and Tristan Watson contributed to analytic plans related to collider bias. Branson Chen contributed to data analyses and data preparation for the symptomatic data set. Maria Sundaram, Jeffrey Kwong, Stefan Baral and Sharmistha Mishra wrote the manuscript. All of authors interpreted the data, critically reviewed and edited the manuscript, gave final approval of the version to be published and agreed to be accountable for all aspects of the work. Sharmistha Mishra and Stefan Baral are co-senior authors.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is non-commercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/ by-nc-nd/4.0/

Funding: This study was funded by the St. Michael’s Hospital Research Innovation Council COVID-19 Research Grant. Stefan Baral, Jeffrey Kwong, Sharmistha Mishra and Maria Sundaram received a research operating grant (VRS-172683) from the Canadian Institutes of Health Research. Sharmistha Mishra is supported by a Tier 2 Canada Research Chair in Mathematical Modeling and Program Science. Jeffrey Kwong is supported by a Clinician-Scientist Award from the University of Toronto Department of Family and Community Medicine.

Data sharing: The data set from this study is held securely in coded form at ICES. While legal data-sharing agreements between ICES and data providers (e.g., health care organizations and government) prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at https://www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Acknowledgements: The authors thank IQVIA Solutions Canada for use of their Drug Information File, as well as Owen Langman for technical assistance. Finally, the authors are grateful to the 14.7 million Ontario residents without whom this research would be impossible.

Disclaimers: The opinions, results, and conclusions reported in this paper are those of the authors and are independent from the funding sources. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI) and by Cancer Care Ontario (CCO). However, the analyses, conclusions, opinions, and statement expressed herein are those of the authors, and not necessarily those of CIHI or CCO. No endorsement by ICES, the Ministries of Health and Long-Term Care (MOHLTC), CIHI or CCO is intended or should be inferred.

This study was supported by ICES, which is funded by an annual grant from the Ontario MOHLTC. The study sponsors did not participate in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Accepted: Apr. 6, 2021

Correspondence to: Jeffrey Kwong, jeff.kwong@utoronto.ca